Want to see CBLL full AI Analyst Report?
CBLL Stock Chart & Stats
$23.73
$1.22(7.21%)
At close: 4:00 PM EDT
$23.73
$1.22(7.21%)
Day’s Range― - ―
52-Week Range$10.85 - $25.63
Previous Close$18.13
Volume442.39K
Average Volume (3M)313.89K
Market Cap
$901.12M
Enterprise Value$632.37M
Total Cash (Recent Filing)$129.26M
Total Debt (Recent Filing)$21.91M
Price to Earnings (P/E)―
Beta0.90
Next Earnings
Nov 17, 2026EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.76
Shares Outstanding38,378,100
10 Day Avg. Volume279,211
30 Day Avg. Volume313,886
Financial Highlights & Ratios
PEG Ratio-0.51
Price to Book (P/B)5.16
Price to Sales (P/S)9.00
P/FCF Ratio-19.28
Enterprise Value/Market Cap0.70
Enterprise Value/Revenue6.20
Enterprise Value/Gross Profit6.98
Enterprise Value/Ebitda-10.03
Forecast
1Y Price Target
$29.50Price Target Upside24.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.97
Revenue Forecast (FY)$115.54M
Bulls Say, Bears Say
Bulls Say
Revenue And Account GrowthStrong growth across product and subscription revenue, combined with expanding hospital adoption, indicates increasing utilization of Ceribell’s platform. A larger installed account base can support recurring software and consumable revenue, while same-store growth may improve the durability of future expansion.
High Gross Margins And Product ExpansionSustained high-80s gross margins provide attractive unit economics and create operating leverage if revenue scales. FDA-cleared enhancements also broaden clinical utility and potential adoption, strengthening the platform’s ability to serve more monitoring needs over the next several quarters.
Liquidity And Manageable LeverageThe company has meaningful liquidity and a relatively low debt-to-equity ratio, giving it flexibility to continue commercial and product investment. The extended credit facility and healthier capital structure reduce immediate financing pressure while Ceribell works toward operating breakeven.
Bears Say
Persistent Unprofitability And Cash BurnCeribell remains dependent on cash reserves and financing because operations are consuming substantial cash. Continued losses can erode equity and limit strategic flexibility if revenue growth does not eventually translate into positive operating cash flow and sustainable profitability.
Operating Expense GrowthExpense growth is currently outpacing the company’s ability to convert revenue into earnings, contributing to a larger GAAP loss despite strong sales and margins. Elevated investment may support future expansion, but it also delays operating leverage and increases the scale required for breakeven.
Delayed Contribution From New ProductsThe newer product initiatives are not expected to materially accelerate revenue in the near term, leaving current performance reliant on the existing seizure-monitoring business. Delayed commercialization increases execution risk and postpones the diversification benefits of the expanded portfolio.
Ceribell, Inc. News
CBLL FAQ
What was Ceribell, Inc.’s price range in the past 12 months?
Ceribell, Inc. lowest stock price was $10.85 and its highest was $25.63 in the past 12 months.
What is Ceribell, Inc.’s market cap?
Ceribell, Inc.’s market cap is $901.12M.
When is Ceribell, Inc.’s upcoming earnings report date?
Ceribell, Inc.’s upcoming earnings report date is Nov 17, 2026 which is in 39 days.
How were Ceribell, Inc.’s earnings last quarter?
Ceribell, Inc. released its earnings results on Aug 10, 2026. The company reported -$0.51 earnings per share for the quarter, missing the consensus estimate of -$0.471 by -$0.039.
Is Ceribell, Inc. overvalued?
According to Wall Street analysts Ceribell, Inc.’s price is currently Undervalued.
Does Ceribell, Inc. pay dividends?
Ceribell, Inc. does not currently pay dividends.
What is Ceribell, Inc.’s EPS estimate?
Ceribell, Inc.’s EPS estimate is -0.51.
How many shares outstanding does Ceribell, Inc. have?
Ceribell, Inc. has 38,378,100 shares outstanding.
What happened to Ceribell, Inc.’s price movement after its last earnings report?
Ceribell, Inc. reported an EPS of -$0.51 in its last earnings report, missing expectations of -$0.471. Following the earnings report the stock price went up 10.415%.
Which hedge fund is a major shareholder of Ceribell, Inc.?
Currently, no hedge funds are holding shares in CBLL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ceribell, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.50 (24.32% Upside)
$29.50 (24.32% Upside)
Blogger Sentiment
Bullish
CBLL Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 89.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $488.7K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
89.13%
12-Months-Change
Fundamentals
Return on Equity
-44.85%
Trailing 12-Months
Asset Growth
-19.91%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Ceribell, Inc.
CeriBell, Inc. specializes in pioneering artificial intelligence (AI)-powered electroencephalography (EEG) solutions designed for the immediate diagnosis and treatment of neurological conditions directly at the patient's bedside. The company's primary offering is the Ceribell System, an innovative, on-site EEG platform engineered to fulfill crucial, previously unmet requirements for patients in urgent medical environments. Beyond the core system, CeriBell also provides single-use EEG headbands and compact, battery-powered recording devices. Originally established in 2014 as Brain Stethoscope, Inc., the company underwent a name change to CeriBell, Inc. in August 2015. Its headquarters are located in Sunnyvale, California.
CBLL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call showcased strong top-line growth, high gross margins, meaningful regulatory clearances, expanding product portfolio (neonate/pediatric/delirium), and favorable reimbursement (NTAP), supported by a solid cash position and improved guidance — all material positive developments. Offsetting these positives are widening GAAP losses, materially higher operating expenses (including stock-based comp and litigation costs), continued negative adjusted EBITDA, and timing uncertainty for revenue contributions from new product initiatives. On balance, the company appears to be executing commercial and technical milestones that should drive future growth, while actively reinvesting and accepting near-term profitability pressure.View all CBLL earnings summariesCBLL Stock 12 Month Forecast
Average Price Target
$29.50
▲(24.32% Upside)
Technical Analysis
Koninklijke Philips
―
ClearPoint Neuro
―
Hyperfine
―
NeuroPace
―
GE Healthcare Technologies Inc
―
Ownership Overview
26.03% Insiders
25.65% Mutual Funds
31.86% Other Institutional Investors
8.18% Public Companies and
Individual Investors